Mickaila Johnston, MD
Nuclear Medicine · Redding
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 4
Offices
4 locations · Nuclear Medicine Associates · Inview Imaging Diagnostics Inc A Professional Medical Corporation · Michael P Sherman MD PHD A Medical Corporation · Hospital Service District No. 1 of Iberia Parish
Looking this up.
Hospitals listed: Iberia Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Johnston’s office to ask if they take your plan before you enroll.
State licence records
1 licence
- Washington IMLC.MD.61395097Physician and Surgeon License Interstate Medical Licensure Compact · since 2022 · expires 2027-06-30Matched by name, not licence number; check the name before relying on it.ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Iberia Medical CenterNew Iberia, LAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Ochsner Health System, which runs 36 hospitals in 3 statesPatients rate it 4 of 5 · 62% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.196, Oct 2024 – Sep 2025
See every measure and the patient survey for Iberia Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 1 worse of 6 measures. Safety: 0 better, 5 the same, 0 worse of 5 measures. Readmissions: 0 better, 9 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.196 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.05) · 366 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.21 (0.8 to 1.63) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 11.2 · 59 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 53 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.4 · 150 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 17.2 · 59 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 1,018 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 1,942 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 2,015 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.99 (0.55 to 5.44) · 348 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.57 (0 to 3.26) · 99 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.49 (0.81 to 4.16) · 315 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.6 (0.82 to 18.37) · 100 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.71 (1.56 to 9.86) · 91 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.71 (0.2 to 3.22) · 69 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.42 (0.48 to 2.36) · 1,405 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 33 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.3 · 83 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 294 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -8.3 · 195 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -37.5 · 197 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 288 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4 to 9.1) · 62 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7.2 to 14.7) · 62 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 32 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19 · 133 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.7 (10.1 to 18.6) · 124 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 168 cases | No different | Jan 2024 – Dec 2024 |
What patients said (424 patients answered, 19% of those asked)
| Cleanliness | 5 |
| Nurse communication | 5 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 5 |
| Recommend hospital | 3 |
| Room was "always" clean | 85% |
| Nurses "always" communicated well | 86% |
| Doctors "always" communicated well | 84% |
| Staff "always" explained | 69% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 82% |
| Doctors "always" listened carefully | 83% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 81% |
| Nurses "always" explained things so they could understand | 84% |
| Nurses "always" listened carefully | 84% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 71% |
| "YES", patients would definitely recommend the hospital | 62% |
| Staff "always" explained possible side effects | 57% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$263,345
Medicare paid this office $263,345 for 298 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | 64 | $139,459 | $2,179 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 73 | $26,380 | $361 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 64 | $17,534 | $274 |
| Nuclear medicine study of bone taken at different times | 30 | $7,603 | $253 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 76 | $5,146 | $35 |
See all 15 services
| Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | 64 | $139,459 | $2,179 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 73 | $26,380 | $361 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 64 | $17,534 | $274 |
| Nuclear medicine study of bone taken at different times | 30 | $7,603 | $253 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 76 | $5,146 | $35 |
| Nuclear medicine study of stomach to assess emptying | 15 | $3,632 | $242 |
| Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 15 | $3,396 | $226 |
| Nuclear medicine study of bone and/or joint whole body | 14 | $2,917 | $208 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 29 | $2,884 | $99 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 25 | $1,237 | $49 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 48 | $1,144 | $24 |
| Injection, regadenoson, 0.1 mg | 46 | $1,115 | None |
| Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 16 | $691 | $43 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 40 | $662 | $17 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 45 | $513 | $11 |
Who their Medicare patients are
298 Original Medicare patients in 2024. Average age 74 · Under 65 7% · 85 and older 10% · Women 56% · Also on Medicaid 17% · Health risk score 1.40. At or below the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 75% · Diabetes 36% · Coronary heart disease 28% · Cancer 28% · Chronic kidney disease 27% · Atrial fibrillation 26% · Depression 24% · Heart failure 21% · COPD 19% · Stroke 10% · Dementia 9%.
The office billed $687,936, Medicare allowed $334,240 and paid $263,345; for 1,513 services of 41 kinds; $2,214 of it was for drugs given in the office and $261,131 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 298 | 1,513 | 74 | 1.40 | $687,936 | $263,345 |
| 2023 | 293 | 814 | 75 | 1.38 | $877,566 | $381,080 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| Iodine 1-123 ioflupane, diagnostic, per study dose, up to 5 millicuries | 56 | $122,848 | $2,194 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 67 | $110,114 | $1,449 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 70 | $22,497 | $281 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 61 | $18,421 | $302 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 32 | $10,643 | $333 |
| Nuclear medicine study of bone and/or joint whole body | 45 | $10,125 | $225 |
| Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries | 14 | $7,764 | $555 |
| Nuclear medicine study of bone taken at different times | 26 | $7,078 | $272 |
| Nuclear medicine study of lymphatic system | 14 | $3,917 | $280 |
| Nuclear medicine study of whole body for thyroid cancer | 14 | $3,458 | $247 |
| Injection, regadenoson, 0.1 mg | 15 | $2,835 | None |
| Iodine i-131 sodium iodide capsule(s), diagnostic, per millicurie | 12 | $2,064 | $65 |
| Technetium tc-99m sestamibi, diagnostic, per study dose | 29 | $1,806 | $32 |
| Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 71 | $824 | $12 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) | 28 | $638 | $23 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 15 | $254 | $17 |
| Injection, aminophyllin, up to 250 mg | 12 | $67 | None |
Money from drug and device companies
$198 in 2025
| 2025 | 4 | 4 | None | $198 |
| 2023 | 1 | 1 | None | $56 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Alnylam Pharmaceuticals | Amvuttra | $86 | 1 payment
|
| Telix Pharmaceuticals | Illuccix | $47 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $46 | 1 payment
|
| Ge Healthcare | None | $19 | 1 payment
|
See all 4 published payments
| Ge Healthcare | Meals · 2025-10-07 | None | $19 |
| Progenics Pharmaceuticals | Meals · 2025-03-15 | Pylarify | $46 |
| Telix Pharmaceuticals | Meals · 2025-03-14 | Illuccix | $47 |
| Alnylam Pharmaceuticals | Meals · 2025-02-01 | Amvuttra | $86 |
See earlier years (2023)
2023: $56
| Novartis Pharmaceuticals | Cosentyx | $56 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 100.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1336105386
- Licence
- OR MD25475Washington IMLC.MD.61395097: Active
- Trained
- Uniformed Services Uhs Fe Hebert School of Med, 2003
- Group
- Nuclear Medicine Associates · Inview Imaging Diagnostics Inc A Professional Medical Corporation · Michael P Sherman MD PHD A Medical Corporation · Hospital Service District No. 1 of Iberia Parish
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207U00000X (207U00000X)
- Mailing address
- 2150 Thresher Ave, Silverdale, WA, 98315
- NPI first listed
- 2006-04-26
- NPI last updated
- 2025-07-01
- NPI record certified
- 2025-07-01
This is when the NPI record was last certified, not a medical board exam.